Jiangsu Zhongxin Pharmaceutical

Jiangsu Zhongxin Pharmaceutical is a clinical-stage biopharmaceutical company based in China that specializes in the development of innovative biological drugs for metabolic and neurological conditions. The company's pipeline is highlighted by multi-target agonists for obesity and diabetes, including ZX2021 (a GLP-1/GIP/GCG triple receptor agonist) and ZX2010 (a GLP-1/GIP dual receptor agonist), both of which are in Phase 2 clinical trials. Additionally, the company is advancing recombinant human nerve growth factor (rhNGF) candidates for ophthalmic and neurological indications. In November 2024, Jiangsu Zhongxin Pharmaceutical was acquired by the prominent Chinese pharmaceutical firm Kangyuan Pharmaceutical (Kanion) to bolster its innovative biologics portfolio.